Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR
Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR
Status: Enrolling
Updated:  6/6/2017
Ohio State University
mi
from
Columbus, OH
Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR
Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR
Status: Enrolling
Updated: 6/6/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR
Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR
Status: Enrolling
Updated:  6/6/2017
University of Pittsburgh
mi
from
Pittsburgh, PA
Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR
Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR
Status: Enrolling
Updated: 6/6/2017
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone
Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone in Patients With Locally/Regionally Advanced/Recurrent Melanoma: A Randomized Efficacy, Safety and Biomarker Study
Status: Enrolling
Updated:  6/6/2017
UPMC Cancer Center - Hillman Cancer Center
mi
from
Pittsburgh, PA
Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone
Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone in Patients With Locally/Regionally Advanced/Recurrent Melanoma: A Randomized Efficacy, Safety and Biomarker Study
Status: Enrolling
Updated: 6/6/2017
UPMC Cancer Center - Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Safety and Immunogenicity of Vaccination With Multi-Epitope Peptide Vaccine Containing MART-1, gp100, and Tyrosinase Peptides Given With the Combination of GMCSF and CpG Oligonucleotide (CpG 7909) in ISA-Oil Adjuvant for Patients With Recurrent Inoperable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  6/21/2017
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Safety and Immunogenicity of Vaccination With Multi-Epitope Peptide Vaccine Containing MART-1, gp100, and Tyrosinase Peptides Given With the Combination of GMCSF and CpG Oligonucleotide (CpG 7909) in ISA-Oil Adjuvant for Patients With Recurrent Inoperable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 6/21/2017
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Optical Imaging of Skin Cancers for Margin Delineation of Non-Melanoma Skin Cancers
Evaluation of Optical Imaging for Margin Delineation of Non-Melanoma Skin Cancers
Status: Enrolling
Updated:  6/27/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Optical Imaging of Skin Cancers for Margin Delineation of Non-Melanoma Skin Cancers
Evaluation of Optical Imaging for Margin Delineation of Non-Melanoma Skin Cancers
Status: Enrolling
Updated: 6/27/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Safety of Either a Single or Two IV Doses of Orbactiv in Subjects With ABSSSI
A Double-Blind, Randomized Study to Evaluate the Safety of Either a Single 1200-mg Intravenous (IV) Dose of Orbactiv™ (Oritavancin) and Placebo or Two IV Doses of Orbactiv™ in Subjects Being Treated for Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Status: Enrolling
Updated:  6/28/2017
South Jersey Infectious Disease
mi
from
Somers Point, NJ
Safety of Either a Single or Two IV Doses of Orbactiv in Subjects With ABSSSI
A Double-Blind, Randomized Study to Evaluate the Safety of Either a Single 1200-mg Intravenous (IV) Dose of Orbactiv™ (Oritavancin) and Placebo or Two IV Doses of Orbactiv™ in Subjects Being Treated for Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Status: Enrolling
Updated: 6/28/2017
South Jersey Infectious Disease
mi
from
Somers Point, NJ
Click here to add this to my saved trials
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
A Phase II Study of Cell Transfer Therapy for Metastatic Melanoma Using 41BB Selected Tumor Infiltrating Lymphocytes Plus IL-2 Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen
Status: Enrolling
Updated:  7/6/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
A Phase II Study of Cell Transfer Therapy for Metastatic Melanoma Using 41BB Selected Tumor Infiltrating Lymphocytes Plus IL-2 Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen
Status: Enrolling
Updated: 7/6/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Use of Shade in U.S. and Australian City Parks
Norms and Built Environment: Use of Shade in U.S. and Australian City Parks
Status: Enrolling
Updated:  7/24/2017
Klein Buendel, Inc
mi
from
Golden, CO
Use of Shade in U.S. and Australian City Parks
Norms and Built Environment: Use of Shade in U.S. and Australian City Parks
Status: Enrolling
Updated: 7/24/2017
Klein Buendel, Inc
mi
from
Golden, CO
Click here to add this to my saved trials
Use of Shade in U.S. and Australian City Parks
Norms and Built Environment: Use of Shade in U.S. and Australian City Parks
Status: Enrolling
Updated:  7/24/2017
Cancer Council Victoria
mi
from
Melbourne,
Use of Shade in U.S. and Australian City Parks
Norms and Built Environment: Use of Shade in U.S. and Australian City Parks
Status: Enrolling
Updated: 7/24/2017
Cancer Council Victoria
mi
from
Melbourne,
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
mi
from
San Francisco, CA
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
mi
from
Santa Monica, CA
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
mi
from
New Haven, CT
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
mi
from
New Haven, CT
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
mi
from
Jacksonville, FL
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
mi
from
Miami Beach, FL
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
mi
from
Chicago, IL
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
mi
from
Lutherville-Timonium, MD
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
mi
from
Lutherville-Timonium, MD
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
mi
from
New York, NY
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
mi
from
Toledo, OH
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
mi
from
Toledo, OH
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated:  7/25/2017
GSK Investigational Site
mi
from
Waratah,
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase II Study of IL-18 in Melanoma Patients
Status: Enrolling
Updated: 7/25/2017
GSK Investigational Site
mi
from
Waratah,
Click here to add this to my saved trials
Strategies to Promote Skin Health
Strategies to Promote Skin Health
Status: Enrolling
Updated:  8/1/2017
San Diego State University
mi
from
San Diego, CA
Strategies to Promote Skin Health
Strategies to Promote Skin Health
Status: Enrolling
Updated: 8/1/2017
San Diego State University
mi
from
San Diego, CA
Click here to add this to my saved trials
Pilot Study of IFN α2b for Melanoma Patients
Pilot Analysis of the Effects of IFN α2b Upon the Molecular Profile of Regional Lymph Nodes in Melanoma Patients With and Without Tumor-Involved Sentinel Lymph Nodes
Status: Enrolling
Updated:  8/3/2017
UPMC - Hillman Cancer Center
mi
from
Pittsburgh, PA
Pilot Study of IFN α2b for Melanoma Patients
Pilot Analysis of the Effects of IFN α2b Upon the Molecular Profile of Regional Lymph Nodes in Melanoma Patients With and Without Tumor-Involved Sentinel Lymph Nodes
Status: Enrolling
Updated: 8/3/2017
UPMC - Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
Epigenetically-Modified Autologous Tumor Cell Vaccs and ISCOMATRIX(TM) Adjuvant With Metronomic Oral Cyclophosphamide and Celecoxib in Pts Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura or Mediastinum
Status: Enrolling
Updated:  8/3/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
Epigenetically-Modified Autologous Tumor Cell Vaccs and ISCOMATRIX(TM) Adjuvant With Metronomic Oral Cyclophosphamide and Celecoxib in Pts Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura or Mediastinum
Status: Enrolling
Updated: 8/3/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated:  8/29/2017
GSK Investigational Site
mi
from
Los Angeles, CA
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated: 8/29/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated:  8/29/2017
GSK Investigational Site
mi
from
San Francisco, CA
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated: 8/29/2017
GSK Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated:  8/29/2017
GSK Investigational Site
mi
from
Philadelphia, PA
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated: 8/29/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated:  8/29/2017
GSK Investigational Site
mi
from
Nashville, TN
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated: 8/29/2017
GSK Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated:  8/29/2017
GSK Investigational Site
mi
from
Houston, TX
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated: 8/29/2017
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated:  8/29/2017
GSK Investigational Site
mi
from
Newcastle,
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Status: Enrolling
Updated: 8/29/2017
GSK Investigational Site
mi
from
Newcastle,
Click here to add this to my saved trials
Multiple Antigen-Engineered DC Vaccine for Melanoma
A Phase I Trial Testing Multiple Antigen-Engineered DC Followed by IFNa2b Boost for Immunization of HLA-Unrestricted Melanoma Patients
Status: Enrolling
Updated:  8/30/2017
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Multiple Antigen-Engineered DC Vaccine for Melanoma
A Phase I Trial Testing Multiple Antigen-Engineered DC Followed by IFNa2b Boost for Immunization of HLA-Unrestricted Melanoma Patients
Status: Enrolling
Updated: 8/30/2017
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Dermatology Research Associate
mi
from
Los Angeles, CA
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Dermatology Research Associate
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Stanford University
mi
from
Palo Alto, CA
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Skin Surgery Medical Group, Inc.
mi
from
San Diego, CA
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Skin Surgery Medical Group, Inc.
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
California Pacific Medical Center Research Institute
mi
from
Santa Rosa, CA
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
California Pacific Medical Center Research Institute
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Advanced Derm & Cosmetic Surg
mi
from
Ormond Beach, FL
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Advanced Derm & Cosmetic Surg
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Skin and Cancer Associates and the Center for Cosmetic Enhancement
mi
from
Plantation, FL
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Skin and Cancer Associates and the Center for Cosmetic Enhancement
mi
from
Plantation, FL
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Emory University Clinic
mi
from
Atlanta, GA
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Emory University Clinic
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Laser & Skin Surgery Center of Indiana
mi
from
Carmel, IN
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Laser & Skin Surgery Center of Indiana
mi
from
Carmel, IN
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Beverly Hospital;Oncology Center Pharmacy
mi
from
Beverly, MA
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Beverly Hospital;Oncology Center Pharmacy
mi
from
Beverly, MA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Saint Louis University School of Medicine; Department of Dermatology
mi
from
Saint Louis, MO
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Saint Louis University School of Medicine; Department of Dermatology
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Long Island Skin Cancer and Dermatologic Surgery
mi
from
Smithtown, NY
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Long Island Skin Cancer and Dermatologic Surgery
mi
from
Smithtown, NY
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Mariwalla Dermatology
mi
from
West Islip, NY
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Mariwalla Dermatology
mi
from
West Islip, NY
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
The Skin Surgery Center
mi
from
Winston-Salem, NC
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
The Skin Surgery Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Ohio State University
mi
from
Columbus, OH
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
Dermatology and Laser Center of Charleston
mi
from
Charleston, SC
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
Dermatology and Laser Center of Charleston
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  8/30/2017
LKH Innsbruck; Universitätsklinik für Dermatologie
mi
from
Innsbruck,
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 8/30/2017
LKH Innsbruck; Universitätsklinik für Dermatologie
mi
from
Innsbruck,
Click here to add this to my saved trials